Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Add-on Study of Pentoxifylline in Cutaneous Leishmaniasis (GT)

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2014 by Centro Internacional de Entrenamiento e Investigaciones Médicas
Sponsor:
Information provided by (Responsible Party):
Centro Internacional de Entrenamiento e Investigaciones Médicas
ClinicalTrials.gov Identifier:
NCT01464242
First received: October 24, 2011
Last updated: March 11, 2014
Last verified: March 2014

October 24, 2011
March 11, 2014
November 2011
December 2014   (final data collection date for primary outcome measure)
  • Primary efficacy outcome: Definitive Cure [ Time Frame: Participants will be followed up to 26 weeks ] [ Designated as safety issue: No ]
    Definitive cure, defined as complete re-epithelialization and absence of inflammatory signs in all cutaneous leishmaniasis lesions, and absence of new leishmaniasis lesions
  • Primary safety outcome: Adverse Events [ Time Frame: Participants will be followed up to 26 weeks ] [ Designated as safety issue: Yes ]
    Clinical and laboratory adverse events will be qualified according to the Common Toxicity Criteria for Adverse Effects (CTCAE). All unexpected non serious adverse events will be notified and expected adverse events of moderate or higher category will be reported. All serious adverse events will be reported.
  • Primary efficacy outcome: Definitive Cure [ Time Frame: Participants will be followed for 26 weeks after the end of treatment, an expected average of 7 months ] [ Designated as safety issue: No ]
    Definitive cure, defined as complete re-epithelialization and absence of inflammatory signs in all cutaneous leishmaniasis lesions, and absence of new leishmaniasis lesions
  • Primary safety outcome: Adverse Events [ Time Frame: Participants will be followed for the duration of treatment, an expected average of 20 days ] [ Designated as safety issue: Yes ]
    Clinical and laboratory adverse events will be qualified according to the CTCAE. All unexpected non serious adverse events will be notified and expected adverse events of moderate or higher category will be reported. All serious adverse events will be reported.
Complete list of historical versions of study NCT01464242 on ClinicalTrials.gov Archive Site
  • In vitro lymphoproliferation [ Time Frame: Participants will be followed for an average of 20 days ] [ Designated as safety issue: No ]
    Proliferation of peripheral blood mononuclear cells (PBMCs) after stimulation invitro with L. panamensis antigens will be measured by tritiated thymidine uptake
  • Cytokine secretion by PBMCs [ Time Frame: Participants will be followed for an average of 20 days ] [ Designated as safety issue: No ]
    Secretion of a panel of cytokines relevant to the inflammatory and immune responses will be measured in supernatants from PBMCs cultured with L. panamensis antigens using Luminex technology
  • Macrophage leishmanicidal capacity [ Time Frame: Participants will be followed for an average of 20 days ] [ Designated as safety issue: No ]
    Macrophages will be differentiated from peripheral blood monocytes and their leishmanicidal capacity will be measured by luminometry after infecton with luciferase-transfected promastigotes.
  • Macrophage inducible nitric oxide synthase (iNOS) expression [ Time Frame: Participants will be followed for an average of 20 days ] [ Designated as safety issue: No ]
    Macrophage expression of iNOS after infection will be measured by quantitative real-time Polymerase Chain Reaction (RT-PCR).
  • In vitro lymphoproliferation [ Time Frame: Participants will be followed for the duration of treatment, an expected average of 20 days ] [ Designated as safety issue: No ]
    Proliferation of peripheral blood mononuclear cells (PBMCs) after stimulation invitro with L. panamensis antigens will be measured by tritiated thymidine uptake
  • Cytokine secretion by PBMCs [ Time Frame: Participants will be followed for the duration of treatment, an expected average of 20 days ] [ Designated as safety issue: No ]
    Secretion of a panel of cytokines relevant to the inflammatory and immune responses will be measured in supernatants from PBMCs cultured with L. panamensis antigens using Luminex technology
  • Macrophage leishmanicidal capacity [ Time Frame: Participants will be followed for the duration of treatment, an expected average of 20 days ] [ Designated as safety issue: No ]
    Macrophages will be differentiated from peripheral blood monocytes and their leishmanicidal capacity will be measured by luminometry after infecton with luciferase-transfected promastigotes.
  • Macrophage inducible nitric oxide synthase (iNOS) expression [ Time Frame: Participants will be followed for the duration of treatment, an expected average of 20 days ] [ Designated as safety issue: No ]
    Macrophages will be differentiated from peripheral blood monocytes and their expression of iNOS after infection will be measured by quantitative RT-PCR.
Not Provided
Not Provided
 
Add-on Study of Pentoxifylline in Cutaneous Leishmaniasis
Therapeutic Gain of Adding the Immunomodulator Pentoxifylline to the Treatment of Cutaneous Leishmaniasis

The purpose of this study is to determine whether adding pentoxifylline to treatment of American cutaneous leishmaniasis with meglumine antimoniate increases the rate and speed of clinical response without diminishing safety, and to identify immune correlates of the healing response.

Failure of first line therapies for cutaneous leishmaniasis is a public health issue. Since pathogenesis of dermal leishmaniasis is mediated by the immune and inflammatory responses, resolution of disease and control of infection are intimately linked to the host response. Several investigations have substantiated "proof of principal" for the therapeutic gain of co-adjuvant immunotherapy. This study will evaluate the efficacy and safety of using pentoxifylline (PTX) as a co-adjuvant in the treatment of cutaneous leishmaniasis with meglumine antimoniate in a randomized, double-blind, controlled trial. One arm will receive meglumine antimoniate and PTX and the other arm will receive meglumine antimoniate plus placebo. Efficacy will be assessed at the end of the treatment, and 5, 7, 13 and 26 weeks after initiation of treatment. Efficacy will be measured as the proportion of patients with definitive cure at 26 weeks after initiation of treatment, and time to healing. Safety will be assessed at the end of treatment with respect to the frequency and severity of adverse events.

Blood samples will be taken to evaluate the effects of PTX invitro and ex vivo on cells of the immune system. Proliferation and secretion of cytokines relevant to the immune and inflammatory responses by peripheral blood mononuclear cells will be measured before and after treatment. Likewise, macrophages will be differentiated from peripheral blood monocytes and infected with a strain of L. panamensis transfected with the luciferase (luc) gene. The investigators will measure the capacity of patient macrophages to kill parasites before and after treatment using a luminometric assay of viable parasite burden. Additionally, the investigators will measure the expression of inducible nitric oxide synthase, an enzyme that is necessary for nitric oxide production, one of the main leishmanicidal mechanisms used by macrophages. The investigators postulate that the use of the co-adjuvant with antimonials will increase the therapeutic response and that indicators predictive of a healing response can be identified by this prospective analysis of the immune response and therapeutic outcome.

Interventional
Phase 2
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Cutaneous Leishmaniasis
  • Drug: Meglumine antimonate
    Glucantime® 20mg/kg/day IM daily for 20 days
    Other Name: Glucantime ®
  • Drug: Placebo
    Placebo 400mg orally 3 times a day for 20 days
  • Drug: Pentoxifylline
    Pentoxifylline 400mg orally 3 times a day for 20 days
  • Experimental: Glucantime® + pentoxifylline
    Glucantime® 20mg/kg/day intramuscular injection (IM) daily for 20 days + pentoxifylline 400mg orally 3 times a day for 20 days.
    Interventions:
    • Drug: Meglumine antimonate
    • Drug: Pentoxifylline
  • Placebo Comparator: Glucantime® + placebo
    Glucantime® 20mg/kg/day IM each day for 20 days + placebo 400mg orally 3 times a day for 20 days.
    Interventions:
    • Drug: Meglumine antimonate
    • Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
100
December 2014
December 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with clinical diagnosis of cutaneous leishmaniasis (parasitologic confirmation or presumptive biopsy plus a positive Montenegro skin test).
  • Age between 18 and 65 years.
  • Lesions of a duration equal to or greater than one month
  • More than one lesion or single lesion greater than 3 cm in diameter.
  • Willingness to participate in the study after being informed through a consent process approved by the institutional ethical review committee

Exclusion Criteria:

  • Pregnant or lactating women, and women who are planning to conceive during the study or that reject the use of birth control methods.
  • Medical conditions that compromise the immune system (HIV infection, neoplasias, diabetes mellitus, autoimmune diseases, or use of corticosteroids, immunomodulators or antineoplastic drugs).
  • Medical conditions that preclude the use of antimonials or pentoxifylline (cardiac, renal, hepatic or pancreatic disease or abnormalities).
  • Alcohol abuse or use of recreational drugs that interfere with adherence to treatment
  • Use of drugs with antileishmanial potential during the previous 13 weeks, including pentavalent antimonials, amphotericin B, miltefosine, and pentamidine
  • Use of Theophylline , anticoagulants or antiarrhythmics.
  • Diffuse or disseminated leishmaniasis.
  • Mucosal involvement secondary to Leishmania infection.
  • Incapacity to attend the study visits or any other condition that according to the investigator could interfere with adherence to study procedures.
Both
18 Years to 65 Years
No
Contact: Alexandra Cossio, RN, MSc +57 +2 5552164 ext 114 acossio@cideim.org.co
Contact: Adriana Navas, Bs, Msc +57 +2 5552164 ext 114 amanazu@cideim.org.co
Colombia
 
NCT01464242
222951928964
Yes
Centro Internacional de Entrenamiento e Investigaciones Médicas
Centro Internacional de Entrenamiento e Investigaciones Médicas
Not Provided
Principal Investigator: Nancy C Saravia, PhD Centro Internacional de Entrenamiento e Investigación Médica
Centro Internacional de Entrenamiento e Investigaciones Médicas
March 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP